CD8A and neoplasm: B lymphocytes are assumed to bind tumor antigens through surface immunoglobulin (Ig) molecules, process them, and then present tumor-derived antigens through major histocompatibility complex classes I and II to induce the activation of both CD8+ cells and CD4+ T lymphocytes [40].